CAMBRIDGE COGNITION HOLDINGS PLC - Results for the year ended 31 December 2025 Q&A Session

Cambridge Cognition Holdings PLC’s 2025 investor update highlights a return to growth momentum, underpinned by strong commercial execution and an expanding addressable market. Sales orders increased 73% year-on-year to £12.8 million, driving a 25% rise in the order book to £16.5 million, providing solid revenue visibility with £9.5 million already underpinned for 2026. While reported revenue declined 10% to £9.4 million due to prior-period sales headwinds, management emphasized improving pipeline strength, tier-one customer focus, and operational efficiency as key drivers of future performance. The company continues to invest selectively in R&D, AI, and its proprietary neuroscience data platforms to enhance margins and unlock new revenue streams, particularly across healthcare and consumer markets via scalable solutions like CANTAB Pathway. Strategic collaborations, including large-scale data initiatives with global partners, are reinforcing its data ecosystem and competitive positioning. Cambridge Cognition is targeting EBITDA breakeven to positive territory while maintaining disciplined cost control and cash flow generation, supported by the repayment of debt facilities and improved working capital management. With a growing CNS market opportunity, robust pipeline, and increased investor engagement, the group remains focused on sustainable revenue growth, margin expansion, and long-term shareholder value creation.